February 6, 2004

Mylan Pharmaceuticals Inc.

UDL Laboratories Inc.

Act 128-1992 amending the Lottery Fund Preservation Act, in part, requires all pharmaceutical manufacturers to have in effect a rebate agreement with the PACE Program if they wish to have their products covered. In effecting the rebate provisions of Act 134- 1996, PACE, the Chronic Renal Disease Program (CRDP) and the Special Pharmaceutical Benefits Program (SPBP) will preclude payment for all products marketed by those manufacturers who either have not signed a PACE rebate agreement or have not complied with the agreement provisions.

Please note the following manufacturers are being added to PACE's non-participating list:

Labeler Code 00378 Mylan Pharmaceuticals Inc.

Labeler Code 51079 UDL Laboratories Inc.

Effective Monday ~ February 9~ 2004, products of Mylan Pharmaceuticals Inc. and UDL Laboratories Inc. are no longer reimbursable.

Questions regarding Mylan's decision should be directed to:

Leah L. Summers, Esq.

Corporate Counsel,

Mylan Pharmaceuticals

(800) 848-0461 Ext. 5522